Date Log
Submitted
August 3, 2020
Published
August 3, 2020
A case study on hemolytic uremic syndrome- leading to acute renal failure
Corresponding Author(s) : Jiguru Prasant
prashant7792@gmail.com
International Journal of Allied Medical Sciences and Clinical Research,
Vol. 3 No. 1 (2015): 2015 Volume 3- Issue -1
Abstract
A 65 yrs female patient was presented with complaints of vomiting, loose stools, pain , fever, high grade chills, giddiness, loss of appetite acute renal failure, hemolytic anemia and thrombocytopenia She was diagnosed with Escherichia coli associated hemolytic-uremic syndrome and treated with plasmapheresis and other medications for 3 weeks. She recovered without sequelae.
Keywords
Hemolytic uremic syndrome
Atypical hemolytic uremic syndrome
Acute kidney injury
Shiga toxin-producing E.coli
Complement factor H
Therapeutic plasma exchange
Jiguru Prasant. (2020). A case study on hemolytic uremic syndrome- leading to acute renal failure. International Journal of Allied Medical Sciences and Clinical Research, 3(1), 66–69. https://doi.org/10.61096/ijamscr.v3.iss1.2015.66-69
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
References
-
[1] Scheiring J, Andreoli SP, Zimmerhackl LB: Treatment and outcome of Shiga-toxin-associated hemolytic uremia syndrome (HUS). Pediatr Nephrol 2008, 23:1749–1760.
[2] Michael M, Elliott EJ, Ridley GF, Hodson EM, Craig JC: Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Cochrane Rev 2009. doi:10.1002/14651858.CD003595.pub2. [http://thecochranereviewlibrary.com]
[3] Legendre CM, Licht C, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DH, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fougue D,Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nurnberger J, Ogawa M, Remuzzi G,Richard T, Sberro-Soussari R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, et al: Terminal Complement inhibitor eculizumab in atypical Hemolytic-Uremia Syndrome. N Engl J Med 2013, 368:2169–2181.
[4] Noris M, Giuseppe R: Atypical hemolytic uremic syndrome. N Engl J Med 2009, 361:1676–1687.
[5] Gould LH, Bopp C, Strockbine N, Atkinson R, Baselski V, Body B, Carey R, Crandall C, Hurd S, Kaplan R, Neill M, Shea S, Somsel P, Tobin-D’Angelo M, Griffin PM, Gener-Smith P: Recommendations for diagnosis of Shiga Toxin producing Escherichia coli infections by clinical laboratories. MMWR 2009, 58:1–14.
[6] Fremeaux-Bacchi V, Fkahouri F, Garnier A, Bienaime’ F, Drgaon-Durey M-A, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschenes G, Lebrachu Y, Zuber J, Loirat C: Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013, 8:554–562.
[7] Hofer J, Janecke AR, Zimmerhackl LB, Riedl M, Rosales A, Giner T, Cortina G, Haindl CJ, Petzelberger B, Pawlik M, Jeller V, Vester U, Gadner B, van Husen M, Moritz ML, Wurzner R, Jungraithmayr T, German-Austrian HUS Study Group: Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2013, 8:407–415.
[8] Caprioli J, Castelletti F, Bucchioni S, Bettinaglio P, Bresin E, Pianette G, Gamba S, Brioschi S, Daina E, Remuzzi G, Noris M, International registry of Recurrent and Familial HUS/TTP: Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Human Molecular Genetics 2003, 12:3385–3395.
[9] Kavanagh D, Goodship T: Genetics and complement in atypical HUS. Pediatr Nephrol 2010, 25:2431–2442.
[10] Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V,de Cordoba R, Pinto S, Goodship THJ, Alberti M, Ribes D, Valoti E, Remuzzi G, Noris M, on behalf of the European Working Party on Complement Genetics in Renal Disease: Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 2013, 24:475–486.
References
[1] Scheiring J, Andreoli SP, Zimmerhackl LB: Treatment and outcome of Shiga-toxin-associated hemolytic uremia syndrome (HUS). Pediatr Nephrol 2008, 23:1749–1760.
[2] Michael M, Elliott EJ, Ridley GF, Hodson EM, Craig JC: Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Cochrane Rev 2009. doi:10.1002/14651858.CD003595.pub2. [http://thecochranereviewlibrary.com]
[3] Legendre CM, Licht C, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DH, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fougue D,Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nurnberger J, Ogawa M, Remuzzi G,Richard T, Sberro-Soussari R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, et al: Terminal Complement inhibitor eculizumab in atypical Hemolytic-Uremia Syndrome. N Engl J Med 2013, 368:2169–2181.
[4] Noris M, Giuseppe R: Atypical hemolytic uremic syndrome. N Engl J Med 2009, 361:1676–1687.
[5] Gould LH, Bopp C, Strockbine N, Atkinson R, Baselski V, Body B, Carey R, Crandall C, Hurd S, Kaplan R, Neill M, Shea S, Somsel P, Tobin-D’Angelo M, Griffin PM, Gener-Smith P: Recommendations for diagnosis of Shiga Toxin producing Escherichia coli infections by clinical laboratories. MMWR 2009, 58:1–14.
[6] Fremeaux-Bacchi V, Fkahouri F, Garnier A, Bienaime’ F, Drgaon-Durey M-A, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschenes G, Lebrachu Y, Zuber J, Loirat C: Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013, 8:554–562.
[7] Hofer J, Janecke AR, Zimmerhackl LB, Riedl M, Rosales A, Giner T, Cortina G, Haindl CJ, Petzelberger B, Pawlik M, Jeller V, Vester U, Gadner B, van Husen M, Moritz ML, Wurzner R, Jungraithmayr T, German-Austrian HUS Study Group: Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2013, 8:407–415.
[8] Caprioli J, Castelletti F, Bucchioni S, Bettinaglio P, Bresin E, Pianette G, Gamba S, Brioschi S, Daina E, Remuzzi G, Noris M, International registry of Recurrent and Familial HUS/TTP: Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Human Molecular Genetics 2003, 12:3385–3395.
[9] Kavanagh D, Goodship T: Genetics and complement in atypical HUS. Pediatr Nephrol 2010, 25:2431–2442.
[10] Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V,de Cordoba R, Pinto S, Goodship THJ, Alberti M, Ribes D, Valoti E, Remuzzi G, Noris M, on behalf of the European Working Party on Complement Genetics in Renal Disease: Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 2013, 24:475–486.
[2] Michael M, Elliott EJ, Ridley GF, Hodson EM, Craig JC: Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Cochrane Rev 2009. doi:10.1002/14651858.CD003595.pub2. [http://thecochranereviewlibrary.com]
[3] Legendre CM, Licht C, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DH, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fougue D,Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nurnberger J, Ogawa M, Remuzzi G,Richard T, Sberro-Soussari R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, et al: Terminal Complement inhibitor eculizumab in atypical Hemolytic-Uremia Syndrome. N Engl J Med 2013, 368:2169–2181.
[4] Noris M, Giuseppe R: Atypical hemolytic uremic syndrome. N Engl J Med 2009, 361:1676–1687.
[5] Gould LH, Bopp C, Strockbine N, Atkinson R, Baselski V, Body B, Carey R, Crandall C, Hurd S, Kaplan R, Neill M, Shea S, Somsel P, Tobin-D’Angelo M, Griffin PM, Gener-Smith P: Recommendations for diagnosis of Shiga Toxin producing Escherichia coli infections by clinical laboratories. MMWR 2009, 58:1–14.
[6] Fremeaux-Bacchi V, Fkahouri F, Garnier A, Bienaime’ F, Drgaon-Durey M-A, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschenes G, Lebrachu Y, Zuber J, Loirat C: Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013, 8:554–562.
[7] Hofer J, Janecke AR, Zimmerhackl LB, Riedl M, Rosales A, Giner T, Cortina G, Haindl CJ, Petzelberger B, Pawlik M, Jeller V, Vester U, Gadner B, van Husen M, Moritz ML, Wurzner R, Jungraithmayr T, German-Austrian HUS Study Group: Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2013, 8:407–415.
[8] Caprioli J, Castelletti F, Bucchioni S, Bettinaglio P, Bresin E, Pianette G, Gamba S, Brioschi S, Daina E, Remuzzi G, Noris M, International registry of Recurrent and Familial HUS/TTP: Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Human Molecular Genetics 2003, 12:3385–3395.
[9] Kavanagh D, Goodship T: Genetics and complement in atypical HUS. Pediatr Nephrol 2010, 25:2431–2442.
[10] Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V,de Cordoba R, Pinto S, Goodship THJ, Alberti M, Ribes D, Valoti E, Remuzzi G, Noris M, on behalf of the European Working Party on Complement Genetics in Renal Disease: Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 2013, 24:475–486.